Compounds > hydrochlorothiazide

hydrochlorothiazide and losartan potassium

hydrochlorothiazide has been researched along with losartan potassium in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19901 (20.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Hilden, M; Hilden, T; Leth, A1
Agharazii, M; Larivière, R; Lebel, M; Rodrigue, ME1
Hemmelder, MH; Kluin-Nelemans, HC; Laverman, GD; Navis, G; Sinkeler, SJ; Slagman, MC; Vogt, L; Waanders, F1
Thornton, SN1

Trials

1 trial(s) available for hydrochlorothiazide and losartan potassium

ArticleYear
Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:10

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Cross-Over Studies; Diuretics; Double-Blind Method; Drug Therapy, Combination; Erythropoietin; Female; Humans; Hydrochlorothiazide; Kidney; Losartan; Male; Middle Aged; Proteinuria

2010

Other Studies

4 other study(ies) available for hydrochlorothiazide and losartan potassium

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
High haemoglobin values during medical treatment of hypertension.
    British medical journal, 1968, Jul-20, Volume: 3, Issue:5611

    Topics: Adult; Aged; Antihypertensive Agents; Creatinine; Diuretics; Erythropoietin; Female; Glomerulonephritis; Hematocrit; Hemoglobinometry; Humans; Hydrochlorothiazide; Male; Methyldopa; Middle Aged; Polycythemia; Polythiazide; Pyelonephritis; Renal Artery Obstruction; Triamterene

1968
Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
    American journal of hypertension, 2006, Volume: 19, Issue:12

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Captopril; Disease Models, Animal; Drug Therapy, Combination; Erythropoietin; Hydralazine; Hydrochlorothiazide; Hypertension; Kidney; Kidney Failure, Chronic; Losartan; Nephrectomy; Rats; Rats, Wistar; Recombinant Proteins; Renin-Angiotensin System; Reserpine; Time Factors; Uremia

2006
RAAS blockade in combination with diuretic therapy increases urine excretion, which in turn increases drinking and thus reduces erythropoietin and proteinuria.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:7

    Topics: Chronic Disease; Diuretics; Drinking Behavior; Drug Therapy, Combination; Erythropoietin; Hemodilution; Hemoglobins; Humans; Hydrochlorothiazide; Kidney Diseases; Losartan; Proteinuria; Renin-Angiotensin System; Urination

2010